Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response (Subklasse)
Treatment in Patients With Recurrent Infections and IgG Subclass Deficiency, and/or Deficient Anti-Polysaccharide Antibody Response
Sponsor: Prothya Biosolutions
Listed as NCT00522821, this PHASE4 trial focuses on IgG Deficiency and Infections and remains completed. Sponsored by Prothya Biosolutions, it has been updated 8 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2022 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Jul 2019 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Nov 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Prothya Biosolutions
For direct contact, visit the study record on ClinicalTrials.gov .